SALIM VIRANI to Triglycerides
This is a "connection" page, showing publications SALIM VIRANI has written about Triglycerides.
Connection Strength
1.830
-
Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. Curr Atheroscler Rep. 2020 06 03; 22(7):25.
Score: 0.579
-
What is really new in triglyceride guidelines? Curr Opin Endocrinol Diabetes Obes. 2023 04 01; 30(2):73-80.
Score: 0.174
-
The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. Endocr Rev. 2019 04 01; 40(2):537-557.
Score: 0.134
-
Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. J Am Coll Cardiol. 2018 07 10; 72(2):156-169.
Score: 0.127
-
Association of low-density lipoprotein pattern with mortality after myocardial infarction: Insights from the TRIUMPH study. J Clin Lipidol. 2017 Nov - Dec; 11(6):1458-1470.e4.
Score: 0.120
-
Differential Lipid Response to Statins Is Associated With Variants in the BUD13-APOA5 Gene Region. J Cardiovasc Pharmacol. 2015 Aug; 66(2):183-8.
Score: 0.104
-
Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. Atherosclerosis. 2015 Sep; 242(1):243-50.
Score: 0.103
-
Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia. Atherosclerosis. 2014 Jun; 234(2):249-53.
Score: 0.094
-
Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care. J Clin Lipidol. 2012 Nov-Dec; 6(6):545-52.
Score: 0.083
-
Barriers to non-HDL cholesterol goal attainment by providers. Am J Med. 2011 Sep; 124(9):876-80.e2.
Score: 0.079
-
Individual Variation in the Distribution of Apolipoprotein B Levels Across the Spectrum of LDL-C or Non-HDL-C Levels. JAMA Cardiol. 2024 Aug 01; 9(8):741-747.
Score: 0.048
-
Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics: Implications for Precision Medicine-Brief Report. Arterioscler Thromb Vasc Biol. 2022 12; 42(12):1461-1467.
Score: 0.043
-
Discordance Between Standard Equations for Determination of LDL?Cholesterol in Patients With?Atherosclerosis. J Am Coll Cardiol. 2022 02 15; 79(6):530-541.
Score: 0.041
-
Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation. 2014 Jan 07; 129(1):77-86.
Score: 0.023
-
Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. J Lipid Res. 2013 Jul; 54(7):1980-7.
Score: 0.022
-
LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J Lipid Res. 2012 Mar; 53(3):556-560.
Score: 0.020
-
Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis. 2011 Dec; 219(2):737-42.
Score: 0.020
-
Lipid management: considerations in acute coronary syndrome. Curr Cardiol Rep. 2008 Jul; 10(4):334-41.
Score: 0.016